US price war continues to plague Nycomed:
This article was originally published in Clinica
The profits warning issued by Nycomed in June (see Clinica No 712, p 11) has been borne out by the Norwegian company's six- month results. Price pressure in the US contrast media market caused profits at Nycomed Imaging to fall 16.7% to NKr 1,012 million ($156 million) in the half-year ended June 30th. Sales were down 5.3% to NKr 2,444 million. Combined sales of Omnipaque, Imagopaque and Visipaque in all markets outside North America increased 13% compared with the 1995 period.